–{•¶‚ÖƒXƒLƒbƒv

ƒXƒ^ƒbƒtSTAFF


‹³Žö@–î–ì@ˆçŽq@(Ikuko Yano, Ph.D.)


@og
@•ºŒÉŒ§

@Š‘®Šw‰ï
@American Society for Clinical Pharmacology and Therapeutics
@International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
@“ú–{–òŠw‰ï
@“ú–{ˆã—ÖòŠw‰ïi‘ã‹cˆõEŠw‰ï”F’èŽw“±–òÜŽtj
@“ú–{—Տ°–ò—Šw‰ïiŽÐˆõEŠw‰ï”F’èŽw“±–òÜŽtj
@“ú–{TDMŠw‰ïi•]‹cˆõj
@“ú–{–ò•¨“®‘ÔŠw‰ïi•]‹cˆõj








“Á–½uŽt@ŽR–{@˜aG@iKazuhiro Yamamoto, Ph.D.j


@og

@“Þ—ÇŒ§
@
@Š‘®Šw‰ï
@International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
@“ú–{–òŠw‰ï
@“ú–{ˆã—ÖòŠw‰ïiŠw‰ï”F’èŽw“±–òÜŽtj
@“ú–{TDMŠw‰ï
@“ú–{t‘Ÿ•a–ò•¨—Ö@Šw‰ïiŠw‰ï”F’èê–å–òÜŽtj
@“ú–{ƒQƒmƒ€–ò—Šw‰ïi—Ž–j





Œ¤‹†ˆõ

Î“c@‹ª—T
_ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È@ˆãŠwŒ¤‹†ˆõ


‘åŠw‰@¶

ˆÉ“¡@—Y‘å
_ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã‰ÈŠwêUiŽÐ‰ïl”ŽŽm‰Û’öj
’†ŽR@—DŽq
_ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã‰ÈŠwêUiŽÐ‰ïl”ŽŽm‰Û’öj
‹g“c@Ê‰Ä
_ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã‰ÈŠwêUi•a—f’f•”j

Šw•”¶

‹à’J@˜aÆ
_ŒË‘åŠwˆãŠw•”
ŠâŠÔ@‹|“Þ
_ŒË–ò‰È‘åŠw@–òŠw—Տ°‹³ˆçƒZƒ“ƒ^[
‘ºì@ˆŸŒõ
_ŒË–ò‰È‘åŠw@–òŠw—Տ°‹³ˆçƒZƒ“ƒ^[
ûMè@”üŒŽ
_ŒË–ò‰È‘åŠw@–òŠw—Տ°‹³ˆçƒZƒ“ƒ^[
‘å–ì@—R‰Ô
—§–½ŠÙ‘åŠw–òŠw•”@ˆã—ÖòŠwŒ¤‹†Žº
‰–Œ©@^—R
_ŒË–ò‰È‘åŠw@–òŠw—Տ°‹³ˆçƒZƒ“ƒ^[
’è’n@—¹
_ŒË–ò‰È‘åŠw@–òŠw—Տ°‹³ˆçƒZƒ“ƒ^[
’·•l@ç‰Ä
_ŒË–ò‰È‘åŠw@–òŠw—Տ°‹³ˆçƒZƒ“ƒ^[
¼ŽR@‰ÄŽÀ
_ŒË–ò‰È‘åŠw@–òŠw—Տ°‹³ˆçƒZƒ“ƒ^[



ƒoƒi[ƒXƒy[ƒX

–òÜŠw•ª–ì

§650-0017
•ºŒÉŒ§_ŒËŽs’†‰›‹æ“í’¬7’š–Ú5-2
_ŒË‘åŠwˆãŠw•”•‘®•a‰@@–òÜ•”

TEL: 078-382-6659
FAX: 078-382-6676
E-mail: yakuken@med.kobe-u.ac.jp